Loading...
Loading...
CADL| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 287.0K |
| Gross Profit | -287.0K |
| Operating Expense | 9,621.0K |
| Operating I/L | -9,633.0K |
| Other Income/Expense | 838.0K |
| Interest Income | 102.0K |
| Pretax | -8,795.0K |
| Income Tax Expense | -940.0K |
| Net Income/Loss | -7,855.0K |
Candel Therapeutics, Inc. is a clinical stage biopharmaceutical company specializing in the development of immunotherapies for cancer patients. The company's lead product, CAN-2409, is undergoing Phase II clinical trials for pancreatic cancer, Phase III trials for prostate cancer, and Phase II trials for lung cancer, with completed Phase Ib/II trials for high-grade glioma treatment. Additionally, the company is developing CAN-3110, currently in Phase I trials for recurrent glioblastoma. Candel Therapeutics, Inc. generates revenue through the development and commercialization of these innovative immunotherapies for various cancer indications.
